West Paces Advisors’s Moderna MRNA Stock Holding History

West Paces Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-36	Closed	-$1.02K	–	425
2025 Q1	$1.02K	Sell	36 -7	-16%	-$248	﹤0.01%	489
2024 Q4	$1.79K	Buy	43 +35	+438%	+$1.67K	﹤0.01%	449
2024 Q3	$535	Sell	8 -1	-11%	-$92	﹤0.01%	514
2024 Q2	$1.07K	Sell	9 -7	-44%	-$886	﹤0.01%	486
2024 Q1	$1.71K	Buy	16 +10	+167%	+$1.01K	﹤0.01%	469
2023 Q4	$597	Buy	+6	New	+$505	﹤0.01%	544
2023 Q3	–	Sell	-11	Closed	-$1.34K	–	551
2023 Q2	$1.34K	Hold	11	–	–	﹤0.01%	473
2023 Q1	$1.69K	Hold	11	–	–	﹤0.01%	476
2022 Q4	$1.98K	Buy	+11	New	+$1.8K	﹤0.01%	436
2022 Q3	–	Sell	-9	Closed	-$1.29K	–	559
2022 Q2	$1.29K	Sell	9 -1	-10%	-$143	﹤0.01%	509
2022 Q1	$1.72K	Buy	+10	New	+$1.68K	﹤0.01%	492
2021 Q3	–	Sell	-23	Closed	-$5.41K	–	617
2021 Q2	$5.41K	Hold	23	–	–	﹤0.01%	424
2021 Q1	$3.01K	Buy	+23	New	+$3.33K	﹤0.01%	404

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

West Paces Advisors's MRNA Position: Q2 2025 in Review

West Paces Advisors sold out of Moderna (MRNA) in Q2 2025, closing a stake of 36 shares — an estimated $1.02K sold.

West Paces Advisors first reported a position in MRNA in Q1 2021 and held it in 13 quarters. The position peaked at $5.41K in Q2 2021. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

West Paces Advisors reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
West Paces Advisors sold 36 Moderna shares in Q2 2025, an estimated $1.02K.
West Paces Advisors first reported a position in Moderna in Q1 2021 and held it in 13 quarters.
West Paces Advisors's Moderna position peaked at $5.41K in Q2 2021.
674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on West Paces Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.